Novel endogenous protein-based strategies to inhibit clinically relevant bacterial AB-type toxins including pertussis toxin - Takeaways - MDSpire

Novel endogenous protein-based strategies to inhibit clinically relevant bacterial AB-type toxins including pertussis toxin

  • By

  • Stefanie Lietz

  • Holger Barth

  • April 17, 2026

  • 0 min

Share

  • 1

    AB-type toxins, including pertussis toxin, are key virulence factors that disrupt cellular functions and contribute to disease pathology.

  • 2

    Pertussis toxin is linked to increasing cases of whooping cough, despite vaccination efforts, particularly affecting children aged 10-14.

  • 3

    Recent data shows a decline in vaccination coverage, contributing to the resurgence of pertussis cases in Europe.

  • 4

    Pertussis toxin enters cells via receptor-mediated endocytosis and disrupts cellular signaling by modifying G-proteins.

  • 5

    Novel therapeutic strategies targeting AB-type toxins, utilizing human proteins, are urgently needed to combat toxin-associated diseases.

Original Source(s)

Novel endogenous protein-based strategies to inhibit clinically relevant bacterial AB-type toxins including pertussis toxin

  • by Stefanie Lietz, Holger Barth

  • April 17, 2026

Related Content

RFK Jr. Takes Health Agenda on the Road

Touring Ohio, RFK Jr. highlights food quality and recovery services while steering attention away from vaccine controversies.

Sustaining herd immunity against measles: Insights from a serological cohort study in an outbreak-free population

31 Live Births Reported Following Uterus Transplant

Single-center series details maternal, obstetric, and neonatal outcomes among recipients with uterine-factor infertility